Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 319Lung Neoplasms 239Small Cell Lung Carcinoma 79Colorectal Neoplasms 26NSCLC 24Breast Neoplasms 22Neoplasms 17Disease 15Adenocarcinoma of Lung 14Neoplasm Metastasis 12Melanoma 11Stomach Neoplasms 10Motor Activity 10Ovarian Neoplasms 8Mesothelioma, Malignant 8Brain Neoplasms 8Pleural Effusion, Malignant 7Mesothelioma 7Head and Neck Neoplasms 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Multiple Pulmonary Nodules 6Endometrial Neoplasms 6Triple Negative Breast Neoplasms 5Thymoma 5Small Cell Lung Cancer Extensive Stage 5SCLC, Extensive Stage 5Recurrence 5Pancreatic Neoplasms 5

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Pathologic Processes × Thoracic × Clear all
NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
122 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Lymphatic Metastasis, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡